mexiletine has been researched along with Neuralgia in 19 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 9.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "To investigate the effects of IV lidocaine on spontaneous and evoked pain (allodynia and hyperalgesia) due to peripheral nerve injury (postherpetic neuralgia or nerve trauma) using quantitative sensory testing." | 5.11 | Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. ( Attal, N; Bouhassira, D; Brasseur, L; Chauvin, M; Rouaud, J, 2004) |
| "Threshold tracking was used to measure multiple excitability indices (strength-duration time constant, rheobase, refractoriness, supernormality, and threshold electrotonus) in median motor axons of 20 patients with neuropathic pain or muscle cramping, before and 3 months after treatment with oral 300 mg mexiletine per day." | 5.11 | The effects of mexiletine on excitability properties of human median motor axons. ( Hattori, T; Hiraga, A; Kanai, K; Kuwabara, S; Misawa, S; Nakata, M; Ogawara, K; Tamura, N, 2005) |
| " In this study, we investigated the effects of M58373 on substance P release from sensory neurons in vitro and pain behaviors/responses in rats, compared with mexiletine." | 3.73 | Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. ( Akada, Y; Amano, K; Fukudome, Y; Itoh, M; Ogawa, S; Yamamoto, I; Yamasaki, F, 2006) |
| "Mechanisms of neuropathic pain relief from lidocaine therapy are yet to be understood." | 2.41 | Systemic lidocaine for neuropathic pain relief. ( Chen, LL; Mao, J, 2000) |
| "The development of hind paw mechanical allodynia was measured after BCAO using the von Frey test." | 1.43 | Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia. ( Harada, S; Matsuura, W; Tokuyama, S, 2016) |
| " Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain." | 1.34 | Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. ( Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Gonzalez, E; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Macintyre, DE; Martin, WJ; McGowan, E; Ok, H; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS, 2007) |
| "Pretreatment with mexiletine, at doses of 3, 10 and 30 mg/kg, i." | 1.33 | Effect of mexiletine on vincristine-induced painful neuropathy in mice. ( Kamei, J; Nozaki, C; Saitoh, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Hoyt, SB | 2 |
| London, C | 2 |
| Ok, H | 1 |
| Gonzalez, E | 1 |
| Duffy, JL | 2 |
| Abbadie, C | 3 |
| Dean, B | 1 |
| Felix, JP | 2 |
| Garcia, ML | 2 |
| Jochnowitz, N | 2 |
| Karanam, BV | 2 |
| Li, X | 2 |
| Lyons, KA | 2 |
| McGowan, E | 2 |
| Macintyre, DE | 1 |
| Martin, WJ | 2 |
| Priest, BT | 2 |
| Smith, MM | 2 |
| Tschirret-Guth, R | 1 |
| Warren, VA | 2 |
| Williams, BS | 1 |
| Kaczorowski, GJ | 2 |
| Parsons, WH | 1 |
| Drizin, I | 1 |
| Gregg, RJ | 1 |
| Scanio, MJ | 1 |
| Shi, L | 1 |
| Gross, MF | 1 |
| Atkinson, RN | 1 |
| Thomas, JB | 1 |
| Johnson, MS | 1 |
| Carroll, WA | 1 |
| Marron, BE | 1 |
| Chapman, ML | 1 |
| Liu, D | 1 |
| Krambis, MJ | 1 |
| Shieh, CC | 1 |
| Zhang, X | 1 |
| Hernandez, G | 1 |
| Gauvin, DM | 1 |
| Mikusa, JP | 1 |
| Zhu, CZ | 1 |
| Joshi, S | 1 |
| Honore, P | 1 |
| Marsh, KC | 1 |
| Roeloffs, R | 1 |
| Werness, S | 1 |
| Krafte, DS | 1 |
| Jarvis, MF | 1 |
| Faltynek, CR | 1 |
| Kort, ME | 1 |
| Thomas-Fowlkes, BS | 1 |
| Iolascon, G | 1 |
| Barohn, RJ | 1 |
| Gajewski, B | 1 |
| Pasnoor, M | 1 |
| Brown, A | 1 |
| Herbelin, LL | 1 |
| Kimminau, KS | 1 |
| Mudaranthakam, DP | 1 |
| Jawdat, O | 1 |
| Dimachkie, MM | 1 |
| Iyadurai, S | 1 |
| Stino, A | 1 |
| Kissel, J | 1 |
| Pascuzzi, R | 1 |
| Brannagan, T | 1 |
| Wicklund, M | 1 |
| Ahmed, A | 1 |
| Walk, D | 1 |
| Smith, G | 1 |
| Quan, D | 1 |
| Heitzman, D | 1 |
| Tobon, A | 1 |
| Ladha, S | 1 |
| Wolfe, G | 1 |
| Pulley, M | 1 |
| Hayat, G | 1 |
| Li, Y | 1 |
| Thaisetthawatkul, P | 1 |
| Lewis, R | 1 |
| Biliciler, S | 1 |
| Sharma, K | 1 |
| Salajegheh, K | 1 |
| Trivedi, J | 1 |
| Mallonee, W | 1 |
| Burns, T | 1 |
| Jacoby, M | 1 |
| Bril, V | 1 |
| Vu, T | 1 |
| Ramchandren, S | 1 |
| Bazant, M | 1 |
| Austin, S | 1 |
| Karam, C | 1 |
| Hussain, Y | 1 |
| Kutz, C | 1 |
| Twydell, P | 1 |
| Scelsa, S | 1 |
| Kushlaf, H | 1 |
| Wymer, J | 1 |
| Hehir, M | 1 |
| Kolb, N | 1 |
| Ralph, J | 1 |
| Barboi, A | 1 |
| Verma, N | 1 |
| Ahmed, M | 1 |
| Memon, A | 1 |
| Saperstein, D | 1 |
| Lou, JS | 1 |
| Swenson, A | 1 |
| Cash, T | 1 |
| Matsuura, W | 1 |
| Harada, S | 1 |
| Tokuyama, S | 1 |
| Weston, RM | 1 |
| Subasinghe, KR | 1 |
| Staikopoulos, V | 1 |
| Jarrott, B | 1 |
| Isose, S | 1 |
| Misawa, S | 2 |
| Sakurai, K | 1 |
| Kanai, K | 2 |
| Shibuya, K | 1 |
| Sekiguchi, Y | 1 |
| Nasu, S | 1 |
| Noto, Y | 1 |
| Fujimaki, Y | 1 |
| Yokote, K | 1 |
| Kuwabara, S | 2 |
| Erichsen, HK | 1 |
| Hao, JX | 1 |
| Xu, XJ | 1 |
| Blackburn-Munro, G | 1 |
| Attal, N | 1 |
| Rouaud, J | 1 |
| Brasseur, L | 1 |
| Chauvin, M | 1 |
| Bouhassira, D | 1 |
| Tamura, N | 1 |
| Hiraga, A | 1 |
| Ogawara, K | 1 |
| Nakata, M | 1 |
| Hattori, T | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Kinchington, PR | 1 |
| Krah, DL | 1 |
| Fleetwood-Walker, SM | 1 |
| Kamei, J | 1 |
| Nozaki, C | 1 |
| Saitoh, A | 1 |
| Akada, Y | 1 |
| Ogawa, S | 1 |
| Amano, K | 1 |
| Fukudome, Y | 1 |
| Yamasaki, F | 1 |
| Itoh, M | 1 |
| Yamamoto, I | 1 |
| Ebell, MH | 1 |
| Carroll, IR | 1 |
| Kaplan, KM | 1 |
| Mackey, SC | 1 |
| Galer, BS | 1 |
| Harle, J | 1 |
| Rowbotham, MC | 1 |
| Mao, J | 1 |
| Chen, LL | 1 |
| Tanelian, DL | 1 |
| Brose, WG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)[NCT02260388] | Phase 4 | 402 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study[NCT02217267] | Phase 3 | 29 participants (Actual) | Interventional | 2014-08-01 | Completed | ||
| Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)[NCT03254394] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| Intravenous Lidocaine for Perioperative and Postoperative Analgesia[NCT03921567] | Phase 4 | 520 participants (Anticipated) | Interventional | 2019-04-15 | Recruiting | ||
| Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271] | 5 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to Due to limited population of research participants.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 53.6 |
| Duloxetine | 55.4 |
| Pregabalin | 56.7 |
| Mexiletine | 51.6 |
"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 56.4 |
| Duloxetine | 56.5 |
| Pregabalin | 60.0 |
| Mexiletine | 54.5 |
"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks
| Intervention | T-Score (Mean) |
|---|---|
| Nortriptyline | 58.9 |
| Duloxetine | 58.9 |
| Pregabalin | 58.3 |
| Mexiletine | 59.1 |
"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks
| Intervention | Norm-Based Standardization Score (Mean) | |
|---|---|---|
| Mental Component Score | Physical Component Score | |
| Duloxetine | 50.9 | 42.1 |
| Mexiletine | 51.3 | 43.7 |
| Nortriptyline | 51.0 | 42.8 |
| Pregabalin | 47.2 | 40.0 |
The cumulative dose of oxaliplatin received over the course (up to 12 cycles) of mFOLFOX6 treatment regimen. It corresponds to the absolute summed up quantity of Oxaliplatin administered to the patient over time. There is no range for this measure. Since this is a dose-limiting neuropathy prevention study, the higher value can be interpreted as better outcome. (NCT03254394)
Timeframe: 24 weeks
| Intervention | mg (Mean) |
|---|---|
| Placebo + FOLFOX | 1161.8 |
| Lidocaine + FOLFOX | 1294.8 |
"The intensity of cold pain and cold unpleasantness is evaluated separately, assessed daily on a 0-10 scale, upon holding a pre-cooled (~8°C) metal cylinder for 10 seconds. the area under the curve of cold pain and cold unpleasantness vs time is calculated per chemotherapy cycle (every two weeks) and serves as a primary outcome measure.~For intervention (lidocaine+FOLFOX) and control (placebo+FOLFOX) groups, the average of cold pain AUC and cold unpleasantness AUC over 7 cycles was calculated. The average AUCs over 7 cycles were compared between study arms.~The AUC is measured as a score on a 0-10 scale multiplied by 14 days and may range between 0 and 140. Higher AUC values represent more intense cold pain/unpleasantness." (NCT03254394)
Timeframe: 14 weeks
| Intervention | score on a scale*days (Mean) | |
|---|---|---|
| pain AUC | unpleasantness AUC | |
| Lidocaine + FOLFOX | 9.5 | 25.4 |
| Placebo + FOLFOX | 16.4 | 33.1 |
Changes in Neuropathic Pain Symptom Inventory (NPSI) descriptors of neuropathic pain over time from baseline to cycle 3(6 weeks), cycle 6 (12 weeks), and the last follow-up (34-36 weeks). The total NPSI score ranges from 0 to 100; a higher NPSI total score represents a worse neuropathy outcome. The changes in scores from baseline are compared between study arms. (NCT03254394)
Timeframe: 6 weeks, 12 weeks, 34-36 weeks
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| 6 weeks visit | 12 weeks visit | last follow-up visit | |
| Lidocaine + FOLFOX | 0 | 0 | 13.5 |
| Placebo + FOLFOX | 0 | 0 | 3.0 |
"Change in CIPN (Chemotherapy-induced peripheral Neuropathy) score (on EORTC QLQ-CIPN20 tool ) from baseline to the Cycle 6 (12 weeks), and from baseline to last follow-up (34-36 weeks). EORTC QLQ-CIPN20 ranges from 0 (no symptoms) to 100 (worst symptoms). A higher score represents worse neuropathy. The changes in scores are compared between study arms.~EORTC QLQ-CIPN20 tool is a quality of life questionnaire (QLQ) from the European Organization for Research and Treatment of Cancer (EORTC) for evaluation of CIPN." (NCT03254394)
Timeframe: 12 weeks and 34-36 weeks
| Intervention | score on a scale (Median) | |
|---|---|---|
| 12 | 34-36 weeks | |
| Lidocaine + FOLFOX | 4 | 37.0 |
| Placebo + FOLFOX | 2 | 17.0 |
Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3
| Intervention | units on the VAS (Mean) |
|---|---|
| CRPS I Pain Subjects | 3.67 |
3 reviews available for mexiletine and Neuralgia
| Article | Year |
|---|---|
Is systemic administration of local anesthetic agents effective for relieving neuropathic pain? A Cochrane Review summary with commentary.
Topics: Anesthetics, Local; Humans; Lidocaine; Mexiletine; Neuralgia; Randomized Controlled Trials as Topic; | 2020 |
Systemic lidocaine or mexiletine for neuropathic pain.
Topics: Administration, Oral; Anesthetics; Evidence-Based Medicine; Humans; Infusions, Intravenous; Lidocain | 2006 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
Systemic lidocaine for neuropathic pain relief.
Topics: Administration, Oral; Analgesics; Animals; Humans; Lidocaine; Mexiletine; Neuralgia; Sodium Channel | 2000 |
4 trials available for mexiletine and Neuralgia
| Article | Year |
|---|---|
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
Topics: Adult; Aged; Analgesics; Bayes Theorem; Comparative Effectiveness Research; Duloxetine Hydrochloride | 2021 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
Systemic lidocaine in pain due to peripheral nerve injury and predictors of response.
Topics: Adult; Aged; Analgesics; Cold Temperature; Cross-Over Studies; Double-Blind Method; Female; Hot Temp | 2004 |
The effects of mexiletine on excitability properties of human median motor axons.
Topics: Action Potentials; Administration, Oral; Adult; Aged; Aged, 80 and over; Anesthetics, Local; Axons; | 2005 |
Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study.
Topics: Administration, Oral; Adult; Aged; Anesthetics, Local; Anti-Arrhythmia Agents; Double-Blind Method; | 1996 |
12 other studies available for mexiletine and Neuralgia
| Article | Year |
|---|---|
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Topics: Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Dogs; Drug Evaluation, | 2007 |
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Ether-A-Go-Go Potassium Channels; Furans; Humans; Male; Mice; Neu | 2008 |
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
Topics: Animals; Benzazepines; Disease Models, Animal; Neuralgia; Rats; Sodium Channel Blockers | 2013 |
Effects of Adjuvant Analgesics on Cerebral Ischemia-Induced Mechanical Allodynia.
Topics: Amines; Analgesics; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antico | 2016 |
Design and assessment of a potent sodium channel blocking derivative of mexiletine for minimizing experimental neuropathic pain in several rat models.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Male; Mex | 2009 |
Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain.
Topics: Adult; Aged; Axons; Electric Conductivity; Electrophysiological Phenomena; Female; Humans; Lidocaine | 2010 |
A comparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain.
Topics: Analgesics; Analysis of Variance; Anesthetics, Local; Animals; Disease Models, Animal; Dose-Response | 2003 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Effect of mexiletine on vincristine-induced painful neuropathy in mice.
Topics: Animals; Arginine; Behavior, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibi | 2006 |
Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
Topics: Analgesics; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Formaldehyde; Ganglia, Spina | 2006 |
Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success.
Topics: Adolescent; Adult; Aged; Anesthetics, Local; Choice Behavior; Chronic Disease; Female; Humans; Kapla | 2008 |
Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine.
Topics: Adult; Aged; Carbamazepine; Female; Humans; Lidocaine; Male; Mexiletine; Neuralgia; Peripheral Nerve | 1991 |